Disease-specific survival

Disease-Specific Survival (DSS) is a term used in the field of oncology to describe the probability that individuals diagnosed with a specific disease will not die from that disease within a given period. It is a measure used to assess the effectiveness of treatments for various cancers and other serious diseases. DSS is an important endpoint in clinical trials and research studies, as it provides insight into the direct impact of a disease on survival, excluding deaths from other causes.

Definition

Disease-specific survival is defined as the time from diagnosis or the start of treatment for a disease until death attributed to that disease. If a patient dies from a cause unrelated to the disease under study, they are not counted as an event in the calculation of DSS. This makes DSS a more precise measure of a treatment's effectiveness against the disease itself, rather than overall survival (OS), which considers death from any cause.

Calculation

The calculation of disease-specific survival involves statistical methods that account for the time to event (in this case, death due to the disease). The Kaplan-Meier estimator is commonly used to estimate survival functions from lifetime data. In clinical trials, DSS is often compared between different treatment groups to assess the efficacy of new therapies.

Importance in Clinical Research

Disease-specific survival is a critical endpoint in clinical trials and epidemiological studies. It helps researchers and clinicians understand the direct impact of a disease on an individual's lifespan, independent of other factors. By focusing on deaths caused by the disease, DSS provides a clearer picture of a treatment's potential benefits.

Comparison with Other Survival Measures

Disease-specific survival is one of several survival measures used in medical research, alongside overall survival (OS) and progression-free survival (PFS). While OS includes all causes of death, PFS measures the time during which a patient's disease does not get worse. DSS offers a more focused view by excluding deaths from causes other than the disease being studied.

Limitations

One limitation of disease-specific survival is the challenge in accurately determining the cause of death. In some cases, it may be difficult to ascertain whether the death was directly due to the disease or other factors. This can introduce bias into the analysis. Additionally, DSS does not account for the quality of life or symptom burden, which are important considerations in palliative care and treatment decision-making.

Conclusion

Disease-specific survival is a valuable measure in the assessment of treatment efficacy in oncology and other fields dealing with life-threatening diseases. By focusing on deaths directly attributable to the disease, it provides a more precise evaluation of a treatment's impact on survival. Despite its limitations, DSS remains a key endpoint in clinical research, guiding the development of new therapies and improving patient care.

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian